JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
83 hedge funds and large institutions have $365M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 11 closing their positions.
Holders
83
Holders Change
+7
Holders Change %
+9.21%
% of All Funds
1.89%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
18
Increased
37
Reduced
15
Closed
11
Calls
–
Puts
$173K
Net Calls
-$173K
Net Calls Change
-$173K
Top Buyers
| 1 |
1
BlackRock
New York
|
$14.8M |
| 2 |
PHS
2
PFM Health Sciences
San Francisco,
California
|
$26.6M |
| 3 |
GPP
3
Great Point Partners
Greenwich,
Connecticut
|
$3.73M |
| 4 |
4
Millennium Management
New York
|
$3.14M |
| 5 |
5
JPMorgan Chase & Co
New York
|
$2.07M |
